Aug 22, 2025 · The virus-like particle vaccine (VIMKUNYA) is manufactured by Bavarian Nordic. The vaccine was licensed by FDA in February 2025 and ACIP approved recommendations for use in U.S. …

UPDATE: On August 22, 2025, the US FDA’s Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva Austria GmbH’s Ixchiq (Chikungunya Vaccine, Live).

Vaccines are approved in the EU as full approval based on strong evidence on correlates of protection with commitments for post-approval clinical studies for confirmation

Feb 14, 2025 · First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the …

Dec 4, 2023 · The FDA has approved Valneva’s chikungunya virus vaccine Ixchiq for adults at risk of exposure to the virus.

Mar 18, 2025 · Beginning today, travel clinics and other healthcare providers will be able to stock VIMKUNYA™.

Feb 17, 2025 · The chikungunya vaccine, VimKunya, is FDA-approved for individuals aged 12 and older, based on successful phase 3 trials. Chikungunya virus, spread by mosquitoes, has caused …

May 8, 2025 · The approval of VIMKUNYA™ marks a pivotal step in combating the spread of chikungunya, providing a tool for prevention in both endemic regions and among travellers.

An Ebola vaccine is a vaccine used to prevent Ebola virus disease (Ebola). As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States is rVSV …

Aug 22, 2025 · On May 9, 2025, FDA and CDC recommended a pause in use of the live-attenuated chikungunya vaccine (IXCHIQ) in older people following reports from several countries of serious …